Literature DB >> 31980363

Targeting the DNA damage response (DDR) by natural compounds.

Jana van Stuijvenberg1, Peter Proksch2, Gerhard Fritz3.   

Abstract

Natural compounds (NC) are an important source of anticancer drugs. The genomic DNA of tumor cells is a major target of conventional anticancer therapeutics (cAT). DNA damage elicits a complex stress response programme termed DNA damage response (DDR), with the PI3-like kinase ATM and ATR being the key regulators. Since the DDR coordinates mechanisms of DNA repair and apoptosis, hence regulating the balance between death and survival, it is an attractive target of novel anticancer strategies. The aim of the study was to identify natural compounds derived from endophytic fungi, lichens, marine sponges or plants that interfere with mechanisms of the DDR. To this end, the cytotoxic and DDR modulating potency of 296 natural compounds, used alone or in combination with the cAT cisplatin (Cis) and doxorubicin (Doxo) was investigated by fluorescence-based analysis of the ATM/ATR-catalyzed S139 phosphorylation of histone 2AX (γH2AX), a surrogate marker of DNA damage-triggered DDR. After initial screening, a total of ten natural compounds were identified that were toxic in pancreatic carcinoma cells and activated the DDR on their own and/or promoted the DDR if used in combination with cAT. Their mode of action was shown to be independent of drug transport mechanisms. Based on their chemical structures, DDR modulatory activity and published data we suggest the marine NC 5-epi-nakijiquinone Q and 5-epi-ilimaquinone as well as the fungal compound secalonic acid F as most promising NC-based drug candidates for future synthesis of DDR-modulating chemical derivatives and their preclinical in vitro and in vivo testing.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Cell death; DNA damage response; Natural compounds; Tumor cell resistance

Mesh:

Substances:

Year:  2020        PMID: 31980363     DOI: 10.1016/j.bmc.2019.115279

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  6 in total

1.  Targeting Mechanisms of the DNA Damage Response (DDR) and DNA Repair by Natural Compounds to Improve cAT-Triggered Tumor Cell Death.

Authors:  Jana Aengenvoort; Marlena Sekeres; Peter Proksch; Gerhard Fritz
Journal:  Molecules       Date:  2022-06-01       Impact factor: 4.927

2.  Increased DNA Polymerase Epsilon Catalytic Subunit Expression Predicts Tumor Progression and Modulates Tumor Microenvironment of Hepatocellular Carcinoma.

Authors:  Haijia Tang; Xiaoxin Hu; Fujiang Xu; Kefei Lin; Wenhao Xu; Haineng Huang; Hailiang Zhang; Yu Xiao; Dongdong Sun; Wangrui Liu; Shiyin Wei
Journal:  J Cancer       Date:  2022-06-03       Impact factor: 4.478

Review 3.  40 Years of Research on Polybrominated Diphenyl Ethers (PBDEs)-A Historical Overview and Newest Data of a Promising Anticancer Drug.

Authors:  Laura Schmitt; Ilka Hinxlage; Pablo A Cea; Holger Gohlke; Sebastian Wesselborg
Journal:  Molecules       Date:  2021-02-13       Impact factor: 4.411

Review 4.  Targeting DNA repair pathway in cancer: Mechanisms and clinical application.

Authors:  Manni Wang; Siyuan Chen; Danyi Ao
Journal:  MedComm (2020)       Date:  2021-12-07

5.  Pro-Apoptotic Activity of the Marine Sponge Dactylospongia elegans Metabolites Pelorol and 5-epi-Ilimaquinone on Human 501Mel Melanoma Cells.

Authors:  Sara Carpi; Egeria Scoditti; Beatrice Polini; Simone Brogi; Vincenzo Calderone; Peter Proksch; Sherif S Ebada; Paola Nieri
Journal:  Mar Drugs       Date:  2022-06-28       Impact factor: 6.085

6.  Protumorigenic Role of Elevated Levels of DNA Polymerase Epsilon Predicts an Immune-Suppressive Microenvironment in Clear Cell Renal Cell Carcinoma.

Authors:  Xiaohui Wu; Haijia Tang; Wen-Hao Xu; Haidan Tang; Shiyin Wei; Aihetaimujiang Anwaier; Haineng Huang; Yuan-Yuan Qu; Hailiang Zhang; Shuai Zhao; Hui Li; Wangrui Liu; Hongjing Chen; Chen Ding; Dingwei Ye
Journal:  Front Genet       Date:  2021-12-07       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.